NEXT Oncology Virginia
Fairfax,US
Recruiting CBP-1019-101
An Open-Label, Non-randomized, Multinational, Multi-center Phase I/Ⅱ Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Bi-Ligand-Drug Conjugate CBP-1019 in Patients with Advanced Solid Tumors.
Locations
Recruiting
The Oncology Institute (TOI) Clinical Research
Cerritos,US
Recruiting
Sarah Cannon
Orlando,US
Recruiting
Northwell Health
Lake success,US
Recruiting
Beijing Cancer Hospital
Beijing,China
Recruiting
Shandong Cancer Hospital
Jinan,China
Recruiting
Chinese Academy Of Medical Sciences In Cancer Hospital
Beijing,China
Recruiting
Jilin University First Hospital
Changchun,China
In preparation
Nanjing Drum Tower Hospital
Nanjing,China
In preparation
Tianjin Cancer Hospital
Tianjin,China
In preparation
Sun Yat-sen University Cancer Center
Guangzhou,China
In preparation
Second Hospital Of Shanxi Medical University
Taiyuan,China
In preparation
Chongqing University Cancer Hospital
Chongqing,China
In preparation
Qilu Hospital of Shandong University
Jinan,China
In preparation
Fudan University Shanghai Cancer Center
Shanghai,China
In preparation
Hunan Cancer Hospital
Changsha,China
In preparation
Henan Cancer Hospital
Zhengzhou,China
In preparation
Union Hospital Tong Ji Medical College Huazhong University Of Science And Technology
Wuhan,China
In preparation
Zhejiang Cancer Hospital
Hangzhou,China
In preparation
Anhui Provincial Hospital
Hefei,China
In preparation
The Sixth Affiliated Hospital,Sun Yat-sen University
Guangzhou,China
In preparation
Harbin Medical University Cancer Hospital
Harbin,China
In preparation